Aim: Human urotensin-(U ) is a cyclic neuropeptide with potent vasoconstrictive activity in the vasculature. The expression of U and its receptor (UT) mRNA is detected at high levels in the brain. We evaluated the relationship between plasma U levels and vascular dementia (VaD) caused by stroke or atherosclerotic small vessel disease. Methods: Carotid artery intima-media thickness (IMT), plaques, plasma levels of immunoreactive U (IR-U ), and atherosclerotic biomarkers were determined in 42 patients with VaD, 197 with Alzheimer's disease (AD), and 47 non-demented elderly controls. Results: Age, gender, body mass index, systolic blood pressure (SBP), fasting plasma glucose, insulin, triglycerides, high-density lipoprotein cholesterol, leptin, and plasminogen activator inhibitor-1 levels were not significantly different among these groups. IR-U , low-density lipoprotein (LDL) cholesterol, lipoprotein(a), lipid peroxides, interleukin-6, and high-sensitive C-reactive protein (hs-CRP) levels, and maximum IMT were significantly higher in VaD than in AD patients or controls. IR-U level showed a significantly positive correlation with SBP or maximum IMT. Multivariate logistic regression analysis revealed a significantly independent association between IR-U levels or increased maximum IMT ( ≥ 1.1 mm) and VaD as compared with SBP, LDL cholesterol, and interleukin-6 levels. Conclusion: Increased plasma IR-U levels and carotid atherosclerosis may be involved in the pathogenesis and progression of VaD.
Introduction
The incidence of vascular dementia (VaD) is high in Japan; nearly 50% of that of senile dementia, and equivalent to that of Alzheimer's disease (AD) 1) . tive protein (hs-CRP) 3) , and a unique pattern of neurotrophic anti-apoptosis factors, i.e., low levels of insulin-like growth factor-1 (IGF-1) and high levels of hepatocyte growth factor (HGF) 4, 5) . Human urotensin-(U ), a cyclic undecapeptide (Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val), serves as an endogenous ligand for G proteincoupled receptor-14 or sensory epithelium neuropeptide-like receptor (SENR) 6) , which was recently renamed UT. Both U and UT are expressed at high levels in the central nervous system (CNS) 7, 8) . There are high-density [
125 I]U binding sites in the lateral septal, medial habenula, and interpenduncular nuclei in rats and the cerebral cortex in humans 7, 8) . Intracerebroventricular injection of U induces anxiogenic-and depressant-like effects in mice, suggesting that U may be involved in psychiatric disorders 9, 10) . Administration of U into the lateral cerebral ventricle increased brain damage following cerebral ischemia in rats 11) . U induces the secretion of amyloid 40-protein (A 40) from the human neuroblastoma cell line IMR32 12) . This peptide is known as the most potent vasoconstrictor identified to date 13) . U in circulating blood is produced mainly by the cardiovascular system, liver, and kidneys 14) . Plasma levels of U are increased in vascular endothelial dysfunction-related diseases, such as hypertension, ischemic heart disease, congestive heart failure, diabetes mellitus, and renal failure, and are positively correlated with systolic blood pressure (BP) and severity of atherosclerosis [14] [15] [16] . U (molecular weight: 1388) is regarded as a biomarker for atherosclerosis and vascular disease 14) ; however, the association between U and VaD is not clear.
We examined associations among plasma U levels, carotid atherosclerosis, and VaD in comparison with AD patients and non-demented elderly subjects.
Methods

Subjects
The study population consisted of 286 elderly Japanese subjects (131 men, 155 women; aged 60 − 97); 197 patients with AD and 42 patients with VaD hospitalized at Showa University Karasuyama Hospital, and 47 age-and sex-matched healthy controls with no evidence of dementia. None of the subjects were taking drugs that influence cognitive performance and had inflammatory diseases. Patients with heart or renal failure and liver cirrhosis known to increase plasma U levels were excluded by history and routine laboratory examination 14) . All participants abstained from smoking for only the night before blood sampling, because smoking within 10 minutes increases plasma U levels 17) . The study was performed in accordance with the declaration of Helsinki and was approved by our Institutional Ethical Review Board. Informed consent was obtained from all subjects and their immediate family.
Dementia Diagnosis
All subjects underwent uniform structured clinical evaluation, which included their medical history, neurological examination, cognitive function assessment, information interview, and standard laboratory tests. Computed tomography (CT) and magnetic resonance imaging (MRI) of the brain were performed for all subjects, and all images were assessed by the same experienced neuroradiologist blinded to the clinical diagnosis or severity of dementia. Diagnosis of dementia was made by the consensus of physicians and neuropsychologists based on the criteria for probable dementia of the National Institute of Neurological and Communicative Disorders and Stroke, the Alzheimer's Disease and Related Disorders Association 18) , and the National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences 19) . Diagnostic classification was made blinded to the results of laboratory examination and carotid ultrasonography. On brain CT and MRI, all VaD patients had significantly more vascular lesions, such as strokes, lacunae, and leukoariosis, than AD patients and controls.
Cognitive function was evaluated using the MiniMental State Examination (MMSE), a 20-item global cognitive function test that includes questions on orientation in time and place, registration, attention and calculation, recall, language, and visual construction that is widely used in clinical practice and scientific studies, with possible scores ranging from 0 − 30 points 20) . MMSE investigates cortical functions, which are important for daily functioning and are severely affected in dementia. Cognitive impairment was defined as a score 24 points 20) .
Past History of Smoking and Alcohol Intake
Information on cigarette smoking and alcohol intake was obtained from each subject or a surrogate regarding the age at which they started smoking, total number of years spent smoking, cigarette consumption, and usual weekly intake of alcoholic beverages over the previous several months. Alcohol intake was converted to daily equivalent in terms of "go," a traditional Japanese unit of sake volume (1 go 180 mL, 22.7 g ethanol). One go corresponds to one bottle (633 mL) of beer, two shots (75 mL) of whisky, or two glasses (180 mL) of wine. Subjects who reported consuming 1 go per week were regarded as drinkers 21) , and smokers were defined by current smoking 10 cigarettes per day for 1 year 22) .
Assays
Blood samples were collected in the morning after overnight fasting and in a non-smoking state. Plasma glucose and serum triglycerides levels (Vitros Slides; Ortho-Clinical Diagnosis, Raritan, NJ, USA) were analyzed by enzymatic methods using automated techniques 2) . Serum levels of LDL cholesterol (BLF Eiken ; Eiken Chemical, Tokyo, Japan) and highdensity lipoprotein (HDL) cholesterol (Vitros Slide) were determined by the precipitation method 2) . Serum levels of apolipoprotein (apo) A1, apoB, and apoE (ApoA1, B, E Auto N; Daiichi Chemicals, Tokyo) were determined by turbidimetric immunoassays 2) . Serum levels of insulin (Lumipulse Presto Insulin; Fujirebio Inc., Tokyo) and hs-CRP (N latex CRP; Dade Behring Inc., Deerfield, IL, USA) were determined by enzyme immunoassay and latex-enhanced immunonephelometric assay, respectively 3) . Serum levels of IGF-1 (IGF-1 IRMA; Daiichi Radioisotope Laboratories, Chiba, Japan) and leptin (Human Leptin RIA kit; Linco Research, Inc., St. Charles, MO, USA) were determined by radioimmunoassay 4, 22) . Serum levels of HGF (HGF Otsuka ELISA kit; Otsuka Pharmaceutical Co., Ltd., Tokyo) and interleukin (IL)-6 (Human IL-6; Fujirebio Inc., Tokyo), and plasma levels of plasminogen activator inhibitor-1 (PAI-1, LPIA • tPAI test; Mitsubishi Chemical Medience Corp., Tokyo) were determined by enzyme-linked immunosorbent assay (ELISA) 22) . Serum adiponectin levels were measured by a sandwich ELISA using a monoclonal antibody against high molecular weight adiponectin purified from human serum 23) .
Immunoreactive U (IR-U ) Measurements
Blood was sampled in EDTA tubes containing aprotinin and immediately spun for 15 minutes at 3,000 rpm. Supernatants were stored at 80 until analysis. Plasma IR-U measurements were carried out with commercial ELISA kits (Urotensin [human]-EIA kit; Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA) according to the manufacturer's instructions. Investigations related to the present study were performed at Phoenix Laboratories to test the immunoreactivity of this antibody with U . The kit showed 100% immunoreactivity with human U , 15.7% with human U -related peptide, 0% with human prepro-U , and 15% and 22% with human U 4 − 11 and 5 − 11 fragments, respectively. The lower detection limit was 0.05 ng/mL and the mean recovery was 96.6%. Our additional studies confirmed the accuracy of the ELISA kit by dilution linearity test using human plasma and human U (Sigma, St Louis, MO, USA). All of the samples (50 L) were processed in a duplicate assay. Intra-and interassay coefficients of variation (CV) were 4% and 9%, respectively.
Carotid Ultrasonography
Carotid atherosclerosis was evaluated by highresolution B-mode ultrasonography using a 7.5-MHz linear-array transducer with axial resolution range from 0.2 − 0.4 mm (SSA-700A; Toshiba Corp., Tokyo). The CV for interobserver variability was found to be 8% and the CV for intraobserver variability was 6%. Maximal IMT and plaque number, as indices of carotid atherosclerosis, were determined by three trained operators blinded to the subjects' clinical records. Ultrasound images were obtained with the subject in the supine position with the neck mildly extended and rotated to the contralateral side, and IMT and plaque number were determined on frozen frames, perpendicular to the vascular walls by scanning bilateral common and internal carotid arteries. IMT was measured in 8 sites of the far walls in the bilateral carotid arteries, excluding plaque, and the unilateral maximum IMT value, which was higher than the other side, was defined as maximum IMT [2] [3] [4] [5] . The upper normal limit of IMT is 1.0 mm, and lesions with focal IMT ≥ 1.1 mm were defined as plaques [2] [3] [4] [5] .
Immunohistochemistry
To identify the localization of IR-U in human carotid atherosclerotic plaques, fluorescent double staining was carried out using human carotid arteries obtained at autopsy. Formalin-fixed sections were incubated with rabbit anti-U polyclonal antibody (Alpha Diagnostic International, San Antonio, TX, USA), and mouse monoclonal antibodies (DakoCytomation A/S, Glostrup, Denmark) of anti--smooth muscle actin ( SMA), a VSMC marker, anti-CD68, a macrophage marker, or anti-von Willebrand Factor (vWF), an EC marker. Alexa 488-labeled anti-mouse and Alexa 546-labeled anti-rabbit antibodies (Molecular Probes) were used as secondary antibodies. Sections were then examined using a Nikon E-600 fluorescence microscope (Tokyo).
Statistical Analysis
Results are expressed as the means SEM for continuous variables and frequencies for categorical variables. One-way analysis of variance followed by Bonferroni correction was used to test differences in continuous variables, and the chi-square test was used to analyze differences in categorical data. Pearson's correlation coefficient was used to analyze relationships between the plasma IR-U level and other continuous variables. Univariate and multivariate logistic regression analyses were performed in 286 subjects to assess independent risk factors for VaD; associations were calculated as odds ratios (OR) with 95% confidence intervals (CI). Statistics were performed with Statview Version 5.0 (Abacus Concepts Inc., Berkeley, CA). A p value of 0.05 was considered significant.
Results
Clinical Characteristics and Laboratory Parameters of VaD and AD Patients and Non-Demented Controls
The clinical characteristics of VaD and AD patients, and non-demented controls are summarized in Table 1 . Mean age, male ratio, body mass index, and prevalence of alcohol consumption, smoking, diabetes mellitus, hyperlipidemia, hypertension, ischemic heart disease, and peripheral vascular disease, and systolic and diastolic BP did not differ significantly among the three groups. The prevalence of cerebrovascular disease (CVD), such as stroke and transient ischemic attack ( Table 1) and maximum IMT (Fig. 1A) was significantly greater in VaD than AD patients or controls. AD patients had significantly greater maximum IMT than controls (Fig. 1A) . MMSE scores were significantly lower in VaD and AD patients than controls but did not differ significantly between VaD and AD patients ( Table 1) . The plasma IR-U level was significantly higher in VaD than AD patients or controls, and the level was lowest in AD (Fig. 1B) . As shown in Table 2 , HDL cholesterol, triglycerides, apoA-1, apoB, apoE, glucose, insulin, HGF, leptin, and PAI-1 levels did not differ significantly among the three groups. Serum levels of LDL cholesterol, lipoprotein(a), lipid peroxides, and hs-CRP were significantly higher in VaD than AD patients or controls. Serum adiponectin and IL-6 levels were significantly higher in VaD and AD patients than controls. The serum IGF-1 level was significantly lower in VaD and AD patients than controls, and the level was lowest in AD.
Correlations Between Plasma IR-U Level and Other Parameters in All Subjects
We examined the correlations between the plasma IR-U level and other parameters in 286 subjects. Plasma IR-U levels were positively correlated LDL cholesterol (mg/dL) HDL cholesterol (mg/dL) Triglycerides (mg/dL) ApoA-1 (mg/dL) ApoB (mg/dL) ApoE (mg/dL) Lipoprotein(a) (mg/dL) Lipid peroxides (nmol/mL) Fasting plasma glucose (mg/dL) Insulin ( U/mL) IGF-1 (ng/mL) HGF (ng/mL) Leptin (ng/mL) Adiponectin (mg/mL) PAI-1 (ng/mL) IL-6 (pg/mL) Hs-CRP (ng/mL) cholesterol and IL-6 levels and systolic BP ( Table 3) .
Expression of IR-U in Carotid Atherosclerotic Plaques
Photomicrograph of staining with anti-U antibody shows that IR-U is expressed at high levels in atherosclerotic plaques of human carotid arteries from a patient with CVD (Fig. 3) . Merge images of fluorescent double staining show that IR-U is expressed highly in vascular smooth muscle cells (VSMCs) and sporadically in macrophage foam cells and endothelial cells (ECs).
Discussion
The present study indicated that plasma IR-U and atherosclerotic biomarker (LDL cholesterol, lipoprotein(a), lipid peroxide, IL-6, and hs-CRP) levels and carotid atherosclerosis were significantly greater in VaD than in AD patients or controls. We and others previously showed that plasma levels of vasoactive agents and inflammatory cytokines such as serotonin, hs-CRP, IL-1 , and tumor necrosis factor-, were significantly higher in VaD patients than in AD patients 3, 22, 24) . Atherosclerotic indices, such as carotid IMT and the ankle-to-brachial index, were significantly greater in VaD than in AD 2, 4, 25, 26) . Increased carotid IMT is associated with the severity of intracranial arterial stenosis and VaD 5, 27) . Although no differences in serum apoE levels were found among our three groups, apoE polymorphism ( 4 allele) is well known to be associated with AD rather than VaD 28) . However, recent studies reported that carotid atherosclerosis and apoE polymorphism are observed in Fluorescent double staining was carried out using human carotid arteries obtained at autopsy. Formalin-fixed sections were incubated with rabbit anti-U polyclonal antibody, and mouse monoclonal antibodies against anti-SMA (a VSMC marker), anti-CD68 (a macrophage marker), or anti-vWF (an EC marker). Alexa 488-labeled anti-mouse and Alexa 546-labeled anti-rabbit antibodies were used as secondary antibodies.
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both AD and VaD patients with almost similar incidence 29, 30) . In our present and previous studies 15, 31) , plasma IR-U levels showed a closely positive correlation with carotid maximum IMT as well as BP, suggesting that U may become a reliable biomarker for atherosclerosis. Importantly, it is the first report that both increased plasma IR-U levels and carotid atherosclerosis showed a significantly independent association with VaD. This study provides insights into the combined use of both parameters to predict the risk for VaD.
The expression of U is shown in VSMCs, ECs, and macrophage foam cells within human carotid atherosclerotic plaques. These vascular cells are also the major cell types expressing UT 32, 33) . U acts in an autocrine-paracrine manner in the vessel wall. Levels of U and UT expression are up-regulated by inflammatory cytokines, such as interferon-, IL-6, and IL-1 , and by hypoxia (ischemia) and mechanical stimuli [34] [35] [36] [37] . U contributes to the development of atherosclerosis by inducing macrophage foam cell formation, EC and VSMC proliferation, and extracellular matrix production 14, 38, 39) . U accelerates macrophage foam cell formation by up-regulating acyl-CoA:cholesterol acyltransferase-1 38) , and has synergistic interactions with mildly oxidized LDL in inducing VSMC proliferation at the highest rate among vasoactive agents 40) . Our recent study showed that chronic infusion of U into apoE-knockout mice enhances atherosclerotic lesions 41) . These findings indicate that U contributes to the progression of atherosclerosis in the large and small cerebral arteries, leading to the major etiology of CVD followed by VaD.
There are several potential limitations in the present study. First, there is some controversy as to the use of some immunoassays for measuring U levels. Disparity was found between the results of different assays, such as radioimmunoassay and ELISA from different commercial or in-house sources. One reason for discrepant findings between studies that employ different immunoreactive methodologies might be the differing selectivity of the antibody used for mature U over prepro-U , U -related peptide, and U fragments 17) . Douglas stated that establishing differential assays for immunoreactive and bioactive U may help explain the wide variation in ELISA assasy 42) ; however, such sensitive assays are not yet available. Second, serum levels of adiponectin, known as an anti-atherosclerotic and anti-inflammatory adipocytokine, were significantly higher in patients with VaD and AD than non-demented controls. This finding is in sharp contrast to serum adiponectin levels being decreased in patients with intracranial atherosclerosis 43) . Recent studies showed that serum adiponectin levels are compensatively increased in chronic inflammatory vascular diseases, such as systemic lupus erythematosus or congestive heart failure to repair vascular endothelial damage 44, 45) . In the present study, adiponectin levels increased with the grade of hs-CRP and also were significantly negatively correlated with IGF-1 levels (r 0.28, p 0.0001). Future studies are required to examine whether the decreased IGF-1 levels in dementia observed in our present and previous studies 4, 5) may lead to increased levels of adiponectin. Finally, plasma IR-U levels were rather lower in AD patients than in the age-matched controls. The causal relationship between the reduction of plasma U levels and AD pathogenesis is unclear in the present study. Further studies are needed to clarify this point.
In conclusion, our results suggest that the plasma IR-U level is a candidate biomarker for atherosclerosis, and thus increased IR-U levels along with severe carotid atherosclerosis may act as risk factors for VaD; therefore, blockade of the U /UT system may be a promising therapeutic strategy for VaD.
